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ABSTRACT
A coronary aneurysm (CA) can occur in sirolimus-eluting stent (SES)-implanted coronary lesions. Although several possi-
ble mechanisms have been suggested, the precise pathogenesis of a CA in SES-implanted lesions is still unknown. We report 
a patient with Churg-Strauss syndrome who underwent successful percutaneous coronary intervention with SES and then 
experienced a CA in an SES-implanted coronary lesion. We describe the CA characteristics through the use of coronary angi-
ography, coronary 64-multidetector computed tomography, and intravascular ultrasound and discuss the etiological factors 
for the CA in this patient. (Korean Circ J 2011;41:559-562)
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Introduction
The sirolimus-eluting stent (SES) has provided excellent 
clinical outcomes by significantly reducing the number of 
major adverse cardiac events.
1)2) However, SESs can cause un-
expected vascular complications, such as stent thrombosis
3) 
and a coronary aneurysm (CA)
4) at SES-implanted coronary 
lesions. Furthermore, systemic necrotizing vasculitis, such as 
Churg-Strauss syndrome (CSS), can involve the native coro-
nary artery in the form of coronary ectasia or an aneurysm. Al-
though the precise mechanisms of CA development at SES-
implanted coronary lesions are still unclear, both SESs and 
CSS can precipitate a CA by weakening the coronary vessel 
walls.
5) We report a case of CA at an SES-implanted coronary 
lesion in a patient with CSS and describe the lesion features 
using several imaging modalities.
Case
A 43 year old man presented with ongoing resting chest 
pain for the past 2 hours. He had been diagnosed with CSS 
at another general hospital 4 months earlier. He met the diag-
nostic criteria for CSS
6) with asthma, allergic sinusitis, hype-
reosinophilia, and systemic vasculitis of the skin, and was re-
ceiving oral prednisone and cyclophosphamide. He had no 
other coronary risk factors. An initial electrocardiogram sh-
owed an ST-segment elevation from the V2 to V6 leads. Di-
agnostic coronary angiography (CAG) revealed a total oc-
clusion of the mid-left anterior descending (LAD) coronary 
artery (Fig. 1A). After a manual intracoronary aspiration th-
rombectomy (Export; Medtronic, Santa Rosa, CA, USA) at the 
mid LAD lesion (Fig. 1B), a subsequent CAG revealed dif-
fuse irregular and significant stenosis from the mid to distal 
LAD with restoration of thrombolysis and myocardial in-
farction grade 3 (Fig. 1C). A successful primary percutaneous 
coronary intervention (PCI) was performed with 2 SESs (Cy-
pher; Cordis Johnson and Johnson, Warren, NJ, USA) placed 
from the mid to proximal LAD (diameter×length: 3.0×33 
mm, and 3.5×23 mm) at a pressure of 18 atm (Fig. 1D and E). 
The final CAG showed good angiographic results at the LAD 
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with no cardiac symptoms and was prescribed 75 mg clopi-
dogrel and 100 mg aspirin daily.
A follow-up CAG was performed at 14 months after the 
primary PCI. We substituted coronary 64-multidetector com-
puted tomography (MDCT) for conventional CAG. Three-di-
mensional (3-D) surface reconstruction images from the co-
ronary 64-MDCT revealed good positioning of the two over-
lapping SESs with no neointimal hyperplasia (Fig. 2A). Addi-
tionally, a volume-rendering image on coronary 64-MDCT 
showed no neointimal hyperplasia or stent malapposition 
(Fig. 2B) compared to the final result. 
He was readmitted to our hospital 39 months later with 
atypical chest discomfort for the past 10 days. We performed 
a follow-up coronary 64-MDCT and CAG. The follow-up 
3-D surface reconstruction view on coronary 64-MDCT 
disclosed a fusiform like diffuse enlargement of the LAD at 
the SES-implanted lesion. (Fig. 2C), and the volume-render-
ing image on coronary 64-MDCT showed a crescent-like 
shape to contrast dye filling in around the stent border (Fig. 
2D). A follow-up CAG showed a diffuse multiple conglom-
erate contrast filling in along the stent border without in-stent 
restenosis (Fig. 2E). An intravascular ultrasound revealed 
significant gaps between the SES struts and the vessel wall 
and an enlargement of the external elastic membrane with a 
maximum diameter of 6.59 mm in the proximal portion, 6.42 
mm in the mid portion, and 6.82 mm in the distal portion 
(Fig. 3). We then had the patient undergo an exercise tread-
mill test to confirm myocardial ischemia; however, the result 
was negative. Finally, we decided to treat the patient with me-
dical therapy. The patient is under careful observation and is 
receiving dual antiplatelet therapy.
Discussion
A CA is defined as a segment with a diameter greater than 
1.5 times the normal adjacent artery segment and can be cla-
ssified as fusiform or saccular.
7) A CA at an SES-implanted 
site accompanies stent malapposition. Although the precise 
mechanism of a CA at an SES-implanted site is unclear, sever-
al possible mechanisms, including acute vessel damage during 
coronary intervention, localized hypersensitivity to the poly-
mer, and vascular remodeling as a result of high drug con-
centrations have been postulated.
8) The CAG and coronary 
64-MDCT findings in the present case suggested that the CA 
development may have been related to hypersensitivity to 
the SES at the contact sites between the vessel wall and the st-
ent surface. Because we did not find a CA on the baseline CAG, 
the SES may have played an important role in CA develop-
ment. In contrast, vascular inflammatory responses occur-
ring in patients with CSS may not affect the development of 
a CA, because no elevated eosinophils were found on the 
complete blood count, and serum C-reactive protein was not 
elevated in this patient. Only one case of acute myocardial 
infarction has been reported due to plaque rupture in a patient 
with CSS.
9) Furthermore, previous studies indicate that coro-
nary artery involvement in patients with CSS is uncommon.
10) 
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Fig. 1. A: baseline cranial-view coronary angiography (CAG) demonstrated total occlusion of the mid left anterior descending (LAD) artery. 
B: the manual thrombus aspiration catheter is shown. C: restoration of LAD blood flow after thrombosuction. D and E: two overlapping siro-
limus-eluting stents (SES) were implanted from the distal to the proximal LAD artery lesion after balloon dilation. F: final CAG shows the 
successfully implanted SESs, good thrombolysis, and myocardial infarction flow.Yujung Cho, et al.   561
Sirolimus has an anti-inflammatory property that inhibits 
the local inflammatory response at the stent-implanted lesion 
site. Sirolimus may not only inhibit neointimal growth but also 
endothelial depletion at the stent-implanted site. Endothelial 
depletion caused by sirolimus may trigger the development of 
a CA secondary to smooth muscle cell degeneration.
The natural course and the appropriate treatment for a CA 
remain uncertain. However, it is certain that patients with a CA 
need prolonged aspirin and dual antiplatelet therapy. Surgi-
cal treatment is indicated for patients with a significant CA ob-
structive lesion or evidence of embolization leading to myo-
cardial ischemia and progressive enlargement of the saccular 
type of CA leading to rupture. Because a CA at an SES-im-
planted coronary lesion may have a benign clinical course, it is 
very important to choose the optimal treatment plan carefully.
However, it has not been demonstrated that localized exag-
gerated hypersensitivity due to sirolimus, polymers, or stent 
metal triggers the development of a CA. The development of 
the CA in this patient seemed to be due to more complex pa-
thogenesis than expected, so an in-depth investigation would 
confirm the association between localized hypersensitivity 
vasculitis and incomplete endothelization. 
Fig. 2. A and B: a three-dimensional surface reconstruction and 
volume rendering image view of 64-multidetector computed tomog-
raphy (MDCT) 14 months after primary percutaneous coronary 
intervention revealed good configuration of two overlapping siroli-
mus-eluting stents (SES) and no in-stent restenosis compared with 
the final coronary angiography (CAG). C: follow-up three-dimensio-
nal surface reconstruction view of coronary 64-MDCT at 39 months 
revealed diffuse enlargement of the left anterior descending (LAD) 
artery from the distal to the proximal stent border (triple white ar-
rows). D: volume-rendering image shows crescent-like shaped con-
trast dye filling out of the stent border with a good configuration of 
the two overlapping SESs (triple white arrows). E: follow-up CAG 
shows diffuse multiple conglomeration contrast filling along the st-
ent border without in-stent restenosis (triple black arrows).
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Fig. 3. Intravascular ultrasound assessment revealed a markedly 
enlarged left anterior descending (LAD) external elastic membrane 
(EEM) around the sirolimus-eluting stents (SES) struts. Maximal 
EEM size of the LAD was 6.59 mm at the proximal (p) portion, 6.42 
mm at the mid (m) portion, and 6.82 mm at the distal (d) portion.
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